Merck, H7779-5MG, Retinoic acid p-hydroxyanilide

General description
Retinoic acid p-hydroxyanilide is a synthetic analog of retinoid.
Application
Retinoic acid p-hydroxyanilide has been used:
as a synthetic retinoid to induce apoptosis in SEB-1 sebocytes
as a medium supplement for C2C12 myoblasts to test its effect on ceramide formation
to test in cytotoxicity in T-cell acute lymphoblastic leukemia (T-ALL)

Biochem/physiol Actions
Retinoic acid p-hydroxyanilide, also called fenretinide, increases reactive oxygen species, activates caspases and induces apoptosis. It also inhibits dihydroceramide desaturase, leading to a decrease in ceramide biosynthesis. Fenretinide may elicit anticancer activity in cultured human breast cancer cells. It acts as an insulin antagonist and may be useful in treating insulin resistance. Fenretinide or 4-HPR has chemotherapeutic potential and is cytotoxic to retinoic acid-resistant cancers.
Vitamin A acid analogue with antiproliferative activity; induces apoptosis in malignant hemopoietic cell lines.